MARKETS
Markets

Decoy Therapeutics Says Preclinical Data Show Single Intranasal Dose Of DCOY-CoV Maintains Drug Levels For Up To 7 Days; Expects Clinical Trials In 2027

Sep 29, 2026 · 07:32 AM ET· updated 50m ago

Share
Why It Matters

Decoy Therapeutics found that one nose spray dose lasted a full week. This early lab work hints the drug might work well in people.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.